Orca Investment Management Upped Novo Nordisk A.S. Adr Formerly (NVO) Position; Armistice Capital Has Decreased By $2.16 Million Its Acorda Therapeutics (ACOR) Stake

May 30, 2017 - By Ellis Scott

Armistice Capital Llc decreased Acorda Therapeutics Inc (ACOR) stake by 21.9% reported in 2016Q4 SEC filing. Armistice Capital Llc sold 120,000 shares as Acorda Therapeutics Inc (ACOR)’s stock declined 39.72%. The Armistice Capital Llc holds 428,000 shares with $8.05 million value, down from 548,000 last quarter. Acorda Therapeutics Inc now has $651.19 million valuation. The stock decreased 2.06% or $0.3 on May 26, reaching $14.25. About shares traded. Acorda Therapeutics Inc (NASDAQ:ACOR) has declined 40.68% since May 30, 2016 and is downtrending. It has underperformed by 57.38% the S&P500.

Orca Investment Management Llc increased Novo Nordisk A.S. Adr Formerly (NVO) stake by 24.22% reported in 2016Q4 SEC filing. Orca Investment Management Llc acquired 12,482 shares as Novo Nordisk A.S. Adr Formerly (NVO)’s stock rose 15.20%. The Orca Investment Management Llc holds 64,023 shares with $2.30M value, up from 51,541 last quarter. Novo Nordisk A.S. Adr Formerly now has $81.14 billion valuation. The stock decreased 0.43% or $0.18 during the last trading session, reaching $41.68. About 646 shares traded. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 23.93% since May 30, 2016 and is downtrending. It has underperformed by 40.63% the S&P500.

Since December 1, 2016, it had 0 insider buys, and 7 insider sales for $5.17 million activity. 3,347 Acorda Therapeutics Inc (NASDAQ:ACOR) shares with value of $69,400 were sold by Wasman Jane. 723 Acorda Therapeutics Inc (NASDAQ:ACOR) shares with value of $16,376 were sold by Greene Barry E. Hindman Andrew A. also sold $121,319 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) shares. $833,655 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) was sold by COHEN RON. Shares for $91,594 were sold by LAWRENCE DAVID on Thursday, December 1. Blight Andrew sold $100,774 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) on Thursday, December 1. $50,381 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) was sold by Sabella Lauren M on Thursday, December 1.

Analysts await Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings on July, 27. They expect $-0.04 earnings per share, up 69.23% or $0.09 from last year’s $-0.13 per share. After $-0.41 actual earnings per share reported by Acorda Therapeutics Inc for the previous quarter, Wall Street now forecasts -90.24% EPS growth.

Among 5 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Acorda Therapeutics had 13 analyst reports since August 25, 2015 according to SRatingsIntel. As per Tuesday, August 25, the company rating was downgraded by TheStreet. The company was upgraded on Wednesday, February 15 by Goldman Sachs. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, August 25. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, March 30. Aegis Capital maintained the shares of ACOR in report on Wednesday, January 6 with “Buy” rating. The rating was upgraded by JP Morgan on Wednesday, November 30 to “Overweight”. Janney Capital upgraded the stock to “Buy” rating in Monday, March 13 report. The firm earned “Buy” rating on Tuesday, September 1 by Aegis Capital. As per Tuesday, September 1, the company rating was initiated by Raymond James. Cowen & Co maintained the shares of ACOR in report on Tuesday, August 25 with “Outperform” rating.

Armistice Capital Llc increased Nomad Hldgs Ltd stake by 260,000 shares to 900,000 valued at $8.61 million in 2016Q4. It also upped Histogenics Corp stake by 998,645 shares and now owns 1.26 million shares. Hain Celestial Group Inc (NASDAQ:HAIN) was raised too.

Investors sentiment increased to 0.99 in 2016 Q4. Its up 0.10, from 0.89 in 2016Q3. It increased, as 17 investors sold ACOR shares while 56 reduced holdings. 25 funds opened positions while 47 raised stakes. 46.53 million shares or 2.03% less from 47.49 million shares in 2016Q3 were reported. Point72 Asia (Hong Kong) stated it has 0.01% in Acorda Therapeutics Inc (NASDAQ:ACOR). Blackrock Advsrs Llc invested in 59,765 shares. Scout reported 48,675 shares. Pictet Asset Limited owns 0.01% invested in Acorda Therapeutics Inc (NASDAQ:ACOR) for 146,337 shares. Alphamark Advisors Lc holds 0.36% in Acorda Therapeutics Inc (NASDAQ:ACOR) or 36,748 shares. Moreover, Tower Rech Capital Lc (Trc) has 0.01% invested in Acorda Therapeutics Inc (NASDAQ:ACOR). Jacobs Levy Equity Inc holds 0.08% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 217,786 shares. 65,123 are held by Mutual Of America Cap Ltd Liability Company. Parkside Retail Bank accumulated 0% or 32 shares. Capstone Asset Mgmt has 12,159 shares. Amer has 0% invested in Acorda Therapeutics Inc (NASDAQ:ACOR). 1.65M are held by State Street Corp. D E Shaw And Company holds 0.02% or 693,468 shares in its portfolio. 26,229 were accumulated by Hightower Advisors Lc. Clearbridge Limited Liability Corporation stated it has 0.02% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR).